Materials and Methods: Medical records comprising 40 eyes of 32 patients treated with IVB who previously underwent FLP due to diabetic macular edema (DME) but diagnosed as clinically signifi cant macular edema (CSME), or those with ?250 ?m central macular thickness (CMT) were analyzed retrospectively. Outcome measures were the change in mean best corrected visual acuity (BCVA) and CMT during the one year follow-up period.

Results: Mean CMT were 403.64 ± 118.34 ?m and 319.39 ± 99.57 ?m before and after treatment, respectively. CMT was signifi cantly reduced at the last follow-up visit (p = 0.0001) compared to the baseline. Pre-treatment and post-treatment Log MAR values were 0.45 (range 0.20-0.95) and 0.50 (range 0.30-1.00) before and after treatment. The difference was not signifi cant (p> 0.05).

Conclusion: This study suggests that if the treatment is initiated as prompt FLP and is followed by IVB therapy, good anatomic results may be obtained however; functional benefi t may not be observed. Anti-vascular endothelial growth factor (VEGF) therapy should be the first treatment in diabetic macular edema or be initiated immediately in patients who had FLP treatment before in order to have at least better anatomic results. Keywords : Bevacizumab; diabetic retinopathy; macular edema; laser photocoagulation; optical coherence tomography